A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Inclusion Criteria

• Inclusion Criteria: - Diagnosis of metastatic (Stage IV) prostate cancer (PC), confirmed by either biopsy of a metastatic tumor site or history of localized disease supported by metastatic disease on imaging studies (that is [i.e.], clearly noted in hospital/clinical records) - Signed Informed consent form (ICF) - No condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example [e.g.], compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments - Willing to provide a saliva, blood, and/or archival tumor tissue sample for genomic analysis - No prior poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi) for the treatment of prostate cancer - No prior DNA-repair gene defect test results from a Janssen sponsored interventional trial